Massachusetts Financial Services Co. MA Has $354.57 Million Position in Vertex Pharmaceuticals Incorporated (VRTX)

Massachusetts Financial Services Co. MA raised its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 10.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,839,645 shares of the pharmaceutical company’s stock after purchasing an additional 176,093 shares during the period. Massachusetts Financial Services Co. MA owned approximately 0.72% of Vertex Pharmaceuticals worth $354,574,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Kaizen Advisory LLC boosted its stake in Vertex Pharmaceuticals by 147.3% during the 2nd quarter. Kaizen Advisory LLC now owns 601 shares of the pharmaceutical company’s stock valued at $102,000 after purchasing an additional 358 shares during the last quarter. Mount Yale Investment Advisors LLC purchased a new position in shares of Vertex Pharmaceuticals in the 1st quarter worth $101,000. Sun Life Financial INC boosted its stake in shares of Vertex Pharmaceuticals by 266.1% in the 2nd quarter. Sun Life Financial INC now owns 692 shares of the pharmaceutical company’s stock worth $118,000 after buying an additional 503 shares during the last quarter. Flagship Harbor Advisors LLC purchased a new position in shares of Vertex Pharmaceuticals in the 2nd quarter worth $125,000. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its stake in shares of Vertex Pharmaceuticals by 3,126.1% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 742 shares of the pharmaceutical company’s stock worth $126,000 after buying an additional 719 shares during the last quarter. Institutional investors and hedge funds own 93.54% of the company’s stock.

NASDAQ VRTX opened at $169.48 on Friday. The firm has a market cap of $42.32 billion, a P/E ratio of 211.85, a P/E/G ratio of 1.67 and a beta of 1.48. The company has a current ratio of 5.97, a quick ratio of 3.55 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $136.50 and a fifty-two week high of $194.92.



Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Wednesday, October 24th. The pharmaceutical company reported $1.09 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.02 by $0.07. The company had revenue of $784.54 million for the quarter, compared to the consensus estimate of $782.95 million. Vertex Pharmaceuticals had a return on equity of 22.92% and a net margin of 22.87%. During the same period in the previous year, the business earned $0.53 earnings per share. On average, equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 2.51 EPS for the current year.

A number of equities analysts have recently issued reports on the company. BidaskClub downgraded Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday. Piper Jaffray Companies dropped their price target on Vertex Pharmaceuticals to $217.00 and set an “overweight” rating on the stock in a research note on Friday. BMO Capital Markets dropped their price target on Vertex Pharmaceuticals from $204.00 to $192.00 and set an “outperform” rating on the stock in a research note on Thursday. HC Wainwright upgraded Vertex Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $220.00 price target on the stock in a research note on Friday. Finally, Raymond James set a $201.00 price target on Vertex Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday. Three analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $202.14.

In related news, EVP David Altshuler sold 2,445 shares of Vertex Pharmaceuticals stock in a transaction on Monday, October 1st. The stock was sold at an average price of $194.62, for a total transaction of $475,845.90. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Thomas Graney sold 1,076 shares of Vertex Pharmaceuticals stock in a transaction on Monday, October 1st. The shares were sold at an average price of $193.24, for a total value of $207,926.24. The disclosure for this sale can be found here. Insiders have sold 33,325 shares of company stock worth $6,135,340 over the last quarter. 1.80% of the stock is owned by company insiders.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor.

See Also: Stock Symbol

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply